Introduction
CML is a neoplastic disorder of the hematopoietic stem cells that accounts for 15-20% of newly diagnosed cases of adult leukemia. The causative molecular event in CML is the genomic reciprocal translocation t(9;22)(q34;q11), known as Philadelphia (Ph) chromosome. The consequence of this genomic rearrangement is the formation of the BCR-ABL fusion gene, resulting in the production of a chimeric protein with aberrant tyrosine kinase activity. Inhibition of BCR-ABL kinase activity through Tyrosine Kinase Inhibitors (TKI) treatment is successfully used in Ph+ CML to induce remission from the pathology. However, treatment with TKI does not completely eradicate CML, due to the insensitiveness of CML stem cells to these drugs. [1] [2] [3] Therefore the identification of pathways that can cooperate with BCR-ABL in the development or in the maintenance of CML is mandatory in order to identify additional targets to achieve synthetic lethality in the aim of curing CML. Furthermore, five percent of CML patients lacks BCR-ABL and is affected by a so called atypical CML, a disease with a poorly understood etiology. Recurrent mutations of SETBP1 are described in about 24% of aCML. 4 Due to the absence of BCR-ABL, aCML patients are not eligible to Imatinib treatment and therefore the identification of specific oncogenic mechanisms is essential to develop a molecular therapy. Typically, aCML is characterized by a high incidence of non-recurrent cytogenetic abnormalities, often due to aneuploid karyotypes, [5] [6] [7] suggesting that genes involved in maintenance of genomic stability could be involved in this pathogenesis.
We recently characterized morgana/chp-1 as an essential protein in mouse embryonic development, involved in the regulation of centrosome duplication and genomic stability. 8 In fact, morgana +/-mouse embryonic fibroblasts (MEFs), expressing 50% of the normal morgana level,
show a higher frequency of supernumerary centrosomes, multipolar spindles, aneuploid and polyploid karyotypes. 8 At a molecular level, morgana forms a complex with ROCKI and ROCKII 8 and, by inhibiting ROCK II kinase activity, suppresses centrosome overduplication. 8, 9, 10 Supernumerary centrosomes represent an important characteristic in cancer onset and progression 11 leading to multipolar mitosis, genomic instability 12 and chromothripsis. 13 Accordingly, morgana +/-MEFs acquire transformed features over time in vitro. 8 In addition, morgana +/-mice show increased susceptibility to tumor development in response to chemical mutagens. 8 Here we show that morgana +/-mice develop with age a fatal and trasplantable myeloproliferative disease similar to human aCML, presenting centrosome amplification as well as cytogenetic abnormalities in the BM. Notably, low morgana expression levels were found in the BM of aCML affected patients and in a portion of Ph+ CML. In this latter condition low morgana levels cooperate with BCR-ABL oncogenic signal in promoting ROCK activity, reducing sensitivity to Imatinib treatment.
Methods

Mice
The morgana gene (chordc1) was inactivated by homologous recombination in mouse ES cells as described. 8 The genetic background of the morgana +/-and the wild type mice analyzed was C57BL/6×129SV. The use of animals was in compliance with the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health, and was approved by the Animal Care and Use Committee of the University of Torino.
Immunohistochemistry
Immunohistochemistry experiments were performed on formalin-fixed, paraffin-embedded tissues using the following antibodies: anti-myeloperoxidase (ab45977, Abcam, 1g/ml), anti-P-MLC2
(LS-C16676, LifeSpan Biosciences) and anti-morgana P1/PP0 antibody (10g/ml). 8, 14 Morgana expression level was defined low when staining intensity was lower compared to normal BM specifically in the myeloid progenitor cells. Slides were scored independently by two pathologists.
Furthermore, IHC scoring was also performed using IHC Profiler software.
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Flow cytometry
Hematopoietic cells were obtained from mouse BM, peripheral blood and spleen. After lysis of red blood cells, cells were stained with the indicated antibodies (see supplemental Methods). For each analysis, a total of at least 10,000 cells were analyzed. For intracellular morgana staining Lin + and Lin -BM cells were incubated with antibodies and treated with FIX & PERM (Caltag). Morgana was stained using FITC-coniugated P1/PP0 (5µg/ml). Flow cytometric analyses were carried out on a FACSCalibur using CellQuest Software (Becton Dickinson). analysis, using the dose-response curves generated from the experimental data, using GraphPad PRISM 5 Software. Mouse BM cells were cultured in DMEM (Invitrogen) supplemented with 10% FBS (Invitrogen), 100 U/mL penicillin, and 100 ug/mL streptomycin at 37°C in 5% CO 2 in presence of interleukin-3 (6 ng/ml; 213-13, Peprotech), interleukin-6 (2.5 ng/ml; 216-16, Peprotech) and stem cell factor (50 ng/ml; 250-03, Peprotech) for 48h in presence of Fasudil (10M), LY294002 (Calbiochem) and BEZ235 (Chemdea).
Bone marrow transplantation
Statistics
Two-sided Student's t test and one-way ANOVA was calculated using GraphPad Prism software. P values < 0.05 were considered statistically significant. Data presented with column graphs and error bars represent the average ± SE.
Results
Morgana haploinsufficiency causes a myeloproliferative neoplasm in mice
We assessed the susceptibility of morgana +/-mice to spontaneous tumor formation by monitoring them for 20 months. Figure 1A ). Notably, expansion of monocytes and eosinophils was not observed (supplemental Figure 1B) , while, as reported in other MPD murine models 18 , an increase of reticulocytes was present (supplemental Figure 1C -E). morgana +/-diseased mice also showed hepatomegaly ( Figure 1E and supplemental Figure 1F ) and in 50% of cases, the presence of myeloid infiltrations in the liver, as demonstrated by positive myeloperoxidase staining ( Figure 1F ).
Moreover, they invariably showed splenomegaly ( Figure 1G and supplemental Figure 1G ) and a Figure 1I ). Interestingly, in two morgana +/-diseased mice, we detected the presence of a pool of Mac-1 -c-Kit + cells in peripheral blood, suggesting that the myeloproliferative disease was evolving into blast crisis (supplemental Figure 1H ).
Finally, to distinguish leukemia from less aggressive disturbances of hematopoiesis, we performed BM transplantation experiments. 19 Lineage negative BM cells were purified from BM of morgana +/-diseased mice and wild type littermates and injected into the tail vein of sub-lethally irradiated nude mice. After 3-6 months morgana +/-recipient mice showed clear pathological signs, demonstrating that the hematologic neoplasm of morgana +/-mice is transplantable ( Figure 1L , supplemental Figure 1I -L and supplemental Table 1 ). Notably, in a secondary recipient mouse the pathology progressed toward a more aggressive phenotype as demonstrated by the presence of a pool of c-Kit + cells in peripheral blood ( Figure 1L ), suggesting the clonal evolution of the disorder.
Overall these data indicate that with age, morgana +/-mice develop a fatal and transplantable myeloproliferative disease closely resembling human CML.
To characterize the origin of the disease, we analyzed possible pathological signs in morgana +/-mice at 8 months. No differences were found in peripheral blood counts (supplemental Figure 2A ), in BM subcellular populations (supplemental Figure 2B) , in the presence of dysplastic megakaryocytes in the BM (supplemental Figure 2C) . Moreover, morgana +/-and wild type mice did not differ for hematopoietic stem cell number, basal apoptotic level, proliferation and P-MLC2 expression levels (supplemental Figure 2D -G). BM cells from healthy morgana +/-mice and wild type littermates were subjected to a colony assay to assess their clonogenic potential. The frequency of erythroid, granulocytic and monocytic colonies in morgana +/-mice was comparable to that of wild type mice (supplemental Figure 2H) ; however a slight, but significant, increase in morgana +/-cell replating potential was noticed (supplemental Figure 2I -L), indicating that morgana +/-cells can acquire hyperproliferative capacity. These observations correlate with the increased proliferation rate of morgana +/-MEFs, 8 suggesting that low levels of morgana favor cellular proliferation.
We previously demonstrated that morgana acts as a ROCK inhibitor in primary fibroblasts and that morgana underexpression causes centrosome amplification and genomic instability. Figure 2D ).
Morgana is underexpressed in human aCML and in a subgroup of Ph+ CMLs
To analyze the relevance of Morgana in human pathology, we first evaluated its expression Figure   3D ). Notably, P-MLC2 detection by IHC was inversely correlated with Morgana expression levels in BM from aCML patients compared with the MDS/MPN (case 6) ( Figure 3E ). These observations together with morgana +/-mouse phenotype, strongly suggests that Morgana plays a role in human aCML pathogenesis. Interestingly, CSF3R mutations were absent in all samples tested, while SETPB1 was found mutated in one aCML patient. To assess if Morgana gene (CHORDC1) mutations can be responsible for low morgana expression levels in aCML patients, we screened exome sequencing data obtained from 16 aCML patients. 4 However, no mutations were detectable, suggesting that more complex regulatory mechanisms are involved in Morgana underexpression in this pathology.
To evaluate the possibility that morgana low leukemia cells were addicted to ROCK signaling we treated BM from morgana +/+ and morgana +/-diseased mice with Fasudil (10M) for 48h
and we analyzed cell viability. ROCK inhibition promoted apoptosis induction only in morgana +/-BM ( Figure 3F ), suggesting that ROCK inhibitors may have a therapeutic value in aCML.
Given that oncosuppressor downregulation often cooperates with activated oncogenes in tumor growth and progression, we expanded our analysis to Philadelphia positive CML. IHC analysis on 19 BM patients revealed that Morgana was clearly underexpressed in 16% of patients ( Figure 4A and B and supplemental Figure 3A and 3B). These data were also confirmed by immunofluorescence on CD34 + purified cells (supplemental Figure 3C ).
Given that morgana +/-diseased mice showed centrosome amplification in BM cells, we assessed whether Morgana low Ph+ CML patients showed similar features. It is known that BCR-ABL expression alone induces centrosome amplification (see also Figure 4C Figure 4C ).
Given that centrosome amplification causes aneuploidy, we analyzed metaphases from Ph+ CML and aCML collected at the moment of diagnosis and we observed a correlation between Morgana underexpression and the percentage of aneuploid cells. In particular, BM of Morgana low patients showed the highest levels of aneuploidy ( Figure 4D ).
Low morgana in Ph+ CML predicts a suboptimal response to Imatinib that can be rescued by inhibiting ROCK
Imatinib blocks the activity of BCR-ABL and of its downstream effector ROCK, leading to CML cell apoptosis. 24, 25, 26, 27 Given that low Morgana levels lead to ROCK activation also in Ph+ CML BM cells ( Figure 5A and supplemental Figure 3D ), we reasoned that Morgana underexpression, by sustaining ROCK activity, may cause a suboptimal response to Imatinib treatment. Indeed, as shown in Figure 5B, Figure 4A and B) . The follow up analysis on 22 patients confirmed that Morgana low patients displayed a suboptimal response to Imatinib (supplemental Figure 4C ). Figure   5C ). IC 50 value for K562 empty was 1,0M, while for K562 silenced for morgana was 3,65M
(shmorgana1) and 3,63M (shmorgana2). Moreover, cells downregulated for Morgana showed a reduced apoptotic response to Imatinib ( Figure 5D ). However, when cells were treated with a combination of Imatinib and the ROCK inhibitors Fasudil or Y27632, the apoptotic response was restored to normal levels ( Figure 5D ). Signaling analysis demonstrated that morgana downregulation promotes ROCK activation also in K562 CML cell line, as demonstrated by increased MLC2 and MYPT1 phosphorylation ( Figure 5E ). It has been reported that ROCKI can phoshorylate PTEN, increasing its stability and activity. 28, 29 Moreover, we recently demonstrated that morgana overexpression, by inhibiting ROCK kinase activity, results in reduced PTEN levels.
14 Accordingly, in morgana low K562, PTEN was expressed at higher levels. However, AKT phosphorylation was not significantly lower, likely due to BCR-ABL dependent PI3K hyperactivation ( Figure 5E ). STAT5 has been involved in Imatinib sensitivity. 30 However, STAT5
phosphorylation, albeit showing a slightly upregulation in K562 interfered for morgana, was not significantly different ( Figure 5E ).
Moreover, combined treatment with Imatinib and the ROCK inhibitor Fasudil, significantly increased apoptosis in Morgana low Ph+ CML BM cells ( Figure 5F ). To eliminate the variability due However, as for BCR-ABL addiction, morgana haploinsufficiency could not be exploited to eradicate leukemia stem cells. In fact, the apoptotic response to Fasudil was not significantly different in BCR-ABL KSL derived from morgana +/-versus wild type mice (supplemental Figure   3E -G).
Overall, these data indicate that Morgana underexpression, through ROCK hyperactivation, causes a suboptimal response to TKI in Ph+ CML cells that can be rescued by ROCK inhibitors, pointing to a potential efficacy of ROCK inhibitors in the chronic treatment of Ph+ CML.
Discussion
Here we show that morgana, a chaperone protein [31] [32] [33] [34] [35] and a high incidence of non-recurrent cytogenetic abnormalities, often due to aneuploid karyotypes, 5, 6, 7 suggesting that genes that regulate genomic stability maintenance could be involved in the pathogenesis of aCML. Here we show that Morgana is underexpressed in the BM of all aCML patients tested, suggesting that Morgana underexpression could represent a common feature in aCML. Given that Morgana underexpression correlates with centrosome amplification and aneuploidy, it is tempting to speculate that Morgana plays a role in the onset of this disease in or a combination of the two drugs (Morgana normal: 6 patients, Morgana low: 9 patients). Bars
